This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Depomed Announces The Launch Of LazandaA® (fentanyl) Nasal Spray And The Signature Support™ Program For Patients With Breakthrough Cancer Pain

NEWARK, Calif., Oct. 28, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it has launched Lazanda® (fentanyl) nasal spray with its newly formed dedicated team of regional sales specialists and the new Signature™ Support Program. Lazanda is indicated for the management of breakthrough pain in cancer patients (BTPc) 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

"Breakthrough pain is very common among cancer patients, and can be properly managed to reduce the number and severity of episodes and the interference of daily activities," said Dr. Emil Annabi, Director of Pain Management and Assistant Professor of Anesthesiology at the University of Arizona, Tucson. "Studies show that breakthrough pain is associated with poorer function and higher cost of care, which is why cancer patients need support services so they can focus on getting pain relief and not be troubled by reimbursement and access issues."

Depomed's new Signature Support Program is designed to streamline patient access to Lazanda. Enrollment in the program is simple and easy for patients.  The service provides one-on-one support for healthcare professionals and their patients by offering several services, including:

  • Benefit verification and prior authorization facilitation
  • Reimbursement assistance with co-pay support
  • Eligibility for up to one-month free trial of Lazanda
  • 1-800 reimbursement support hotline
  • Monthly patient prescription reminders

"We recognize that patients with breakthrough cancer pain face many challenges, including reimbursement and access issues," said Jim Schoeneck President and CEO of Depomed, Inc "With the new Signature Support Program, patients can take advantage of a variety of coordinated resources to make sure the process of starting on Lazanda is as simple as possible."

About LazandaLazanda (fentanyl) nasal spray is a prescription medicine used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Lazanda is a Schedule 2 controlled substance and uses the patented PecSys® drug delivery system. Lazanda delivers fentanyl in a rapid, but controlled manner and is designed to deliver a fine mist spray to the nasal membrane. Each spray of Lazanda forms a gel when it contacts the nasal mucosa. The active ingredient is then rapidly absorbed across the mucus membrane and directly into the blood stream.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs